公开(公告)号：EP1606405A2

公开(公告)日：2005-12-21

申请号：EP04721540.5

申请日：2004-03-18

申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  MUSEUM NATIONAL D'HISTOIRE NATURELLE

发明人： ARIMONDO, Paola Barbara ,  BOUTORINE, Alexandre ,  SUN, Jian-Sheng ,  BAILLY, Christian ,  HELENE, Claude ,  GARESTIER, Thérèse

IPC分类号： C12N15/11 ,  A61K31/7088

CPC分类号： C12N15/1132 ,  A61K38/00 ,  C12N15/113 ,  C12N15/1131 ,  C12N15/1135 ,  C12N15/1136 ,  C12N2310/15 ,  C12N2310/314 ,  C12N2310/3181 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/33 ,  C12N2310/3341 ,  C12N2310/3511 ,  C12N2310/53

摘要： The invention relate to the use of a compound of formula A-B-C Wherein A is a DNA sequence-specific ligand capable of simultaneously and specifically recognizing a sequence common to genes of pathological interest; B is a linker arm, said linker arm being bound to the 3' end of A; C is a topoisomerase I posion; for the preparation of a drug for the treatment of a disease brought about by the expression of a gene and said gene is inhibited by the stabilized topoisomerase I-mediated DNA cleavage. Application, particularly, for the treatment of infective microorganism or virus, dismetabolic disease and autoimmune disease.